Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

Beijing Cancer Hospital, Beijing

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Anhui Provincial Hospital, Hefei

Peking Union Medical College Hospital, Beijing

Fujian Cancer Hospital, Fuzhou

Zhujiang Hospital of Southern Medical University, Guangzhou

Shenzhen Qianhai Shekou Free Trade Zone hospital, Shenzhen

The Fourth Hospital of Hebei Medical University, Shijiazhuang

Harbin Medical University Cancer Hospital, Harbin

Henan Cancer Hospital, Zhengzhou

Hubei Cancer Hospital, Wuhan

Zhongnan hospital of Wuhan University, Wuhan

Hunan Cancer Hospital, Changsha

Hunan Provincial People's Hospital, Changsha

Nanjing Drum Tower Hospital, Nanjing

Jilin Cancer Hospital, Changchun

Liaoning Cancer Hospital, Shenyang

Central Hospital Affiliated to Shangdong First Medical University, Jinan

Shandong Cancer Hospital, Jinan

Eastern Hepatobiliary Surgery Hospital, Shanghai

Shanxi Cancer Hospital, Taiyuan

Sichuan Cancer Hospital, Chengdu

Yunnan Cancer Hospital, Kunming

Zhejiang Cancer Hospital, Hangzhou

Beijing Cancer Hospital, Beijing

Beijing Tsinghua Changgeng Hospital, Beijing

Fudan University Shanghai Cancer Hospital, Shanghai

Zhongshan Hospital, Shanghai

Tianjin medical university cancer institute & hospital, Tianjin